KR20190075702A - A composition for postprandial anti-hyperglycemia comprising ascorbic acid and niacin - Google Patents
A composition for postprandial anti-hyperglycemia comprising ascorbic acid and niacin Download PDFInfo
- Publication number
- KR20190075702A KR20190075702A KR1020170177508A KR20170177508A KR20190075702A KR 20190075702 A KR20190075702 A KR 20190075702A KR 1020170177508 A KR1020170177508 A KR 1020170177508A KR 20170177508 A KR20170177508 A KR 20170177508A KR 20190075702 A KR20190075702 A KR 20190075702A
- Authority
- KR
- South Korea
- Prior art keywords
- niacin
- ascorbic acid
- postprandial
- inhibitory activity
- composition
- Prior art date
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title claims abstract description 176
- 235000010323 ascorbic acid Nutrition 0.000 title claims abstract description 88
- 229960005070 ascorbic acid Drugs 0.000 title claims abstract description 88
- 239000011668 ascorbic acid Substances 0.000 title claims abstract description 88
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 title claims abstract description 85
- 229960003512 nicotinic acid Drugs 0.000 title claims abstract description 85
- 235000001968 nicotinic acid Nutrition 0.000 title claims abstract description 85
- 239000011664 nicotinic acid Substances 0.000 title claims abstract description 85
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 230000000291 postprandial effect Effects 0.000 title abstract description 24
- 201000001421 hyperglycemia Diseases 0.000 title abstract description 12
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims description 11
- 239000008280 blood Substances 0.000 abstract description 30
- 210000004369 blood Anatomy 0.000 abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 8
- 230000002792 vascular Effects 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 description 42
- 241000700159 Rattus Species 0.000 description 34
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 30
- 239000008103 glucose Substances 0.000 description 30
- 230000000968 intestinal effect Effects 0.000 description 24
- 229930006000 Sucrose Natural products 0.000 description 18
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 18
- 108010028144 alpha-Glucosidases Proteins 0.000 description 18
- 239000005720 sucrose Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 13
- 102000001746 Pancreatic alpha-Amylases Human genes 0.000 description 9
- 108010029785 Pancreatic alpha-Amylases Proteins 0.000 description 9
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 7
- 102100022624 Glucoamylase Human genes 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000037406 food intake Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 239000004366 Glucose oxidase Substances 0.000 description 5
- 108010015776 Glucose oxidase Proteins 0.000 description 5
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 5
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 5
- 102400000472 Sucrase Human genes 0.000 description 5
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 5
- 102000016679 alpha-Glucosidases Human genes 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 229940116332 glucose oxidase Drugs 0.000 description 5
- 235000019420 glucose oxidase Nutrition 0.000 description 5
- 230000003345 hyperglycaemic effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 235000011073 invertase Nutrition 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 102000011632 Caseins Human genes 0.000 description 4
- 108010076119 Caseins Proteins 0.000 description 4
- 208000002249 Diabetes Complications Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 3
- LWFUFLREGJMOIZ-UHFFFAOYSA-N 3,5-dinitrosalicylic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O LWFUFLREGJMOIZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 108010046301 glucose peroxidase Proteins 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 description 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 description 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 2
- 108010053775 Nisin Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- -1 arginine derivative compound Chemical class 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000008694 endothelial dysfunction Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000010297 nisin Nutrition 0.000 description 2
- 239000004309 nisin Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- VZOPRCCTKLAGPN-ZFJVMAEJSA-L potassium;sodium;(2r,3r)-2,3-dihydroxybutanedioate;tetrahydrate Chemical compound O.O.O.O.[Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O VZOPRCCTKLAGPN-ZFJVMAEJSA-L 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000021246 κ-casein Nutrition 0.000 description 2
- IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 4-nitrophenyl alpha-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 229940074446 sodium potassium tartrate tetrahydrate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 식후 혈당상승억제용 조성물에 관한 것으로, 더욱 상세하게는 아스코르빈산; 니아신; 또는 아스코르빈산 및 니아신;을 유효성분으로 포함하는 식후 혈당상승억제용 조성물에 관한 것이다.The present invention relates to a composition for postprandial blood glucose elevation inhibition, and more particularly, to a composition for inhibiting postprandial hyperglycemia, comprising ascorbic acid; Niacin; Or ascorbic acid and niacin as an active ingredient.
최근 미국당뇨병협회(American Diabetes Association, ADA)에 따르면, 인체의 공복 혈당이 126mg/dL 이상이거나 또는 식사 후 2시간이 지난 혈당이 200mg/dL일 때 이를 당뇨병이라고 정의하고 있다. According to the recent American Diabetes Association (ADA), diabetes is defined as the fasting blood glucose level of the human body is 126 mg / dL or more, or the blood glucose level is 200 mg / dL after 2 hours of eating.
혈당조절은 당뇨병의 예방 및 치료관리에서 가장 중요한 인자이고, 당뇨병의 합병증 유발 가능성을 결정할 수 있는 가장 중요한 인자로 알려져 있다. 혈당은 공복 혈당, 식후 혈당 및 당화혈 색소가 동시에 조절되어야 한다. 특히 식후 혈당은 당뇨병성 혈관 합병증을 유발하는 주된 병리기전이고, 혈당조절이 양호한 정상군이나 당뇨병의 유병기간이 길지 않은 환자에게서 식후 혈당 조절은 당뇨병의 발병이나 당뇨 합병증을 예방하기 위해 매우 중요한 요인이 되고 있다. Glycemic control is the most important factor in the prevention and management of diabetes and it is known to be the most important factor to determine the possibility of complication of diabetes. The fasting blood sugar, postprandial blood glucose and glycosylated hemoglobin should be controlled simultaneously. In particular, postprandial glucose is a major pathway leading to diabetic vascular complications, and in patients with normal blood glucose control or in patients with a long duration of diabetes, postprandial glucose control is a very important factor to prevent diabetes mellitus or diabetic complications .
식후 고혈당은 LDL 산화과정을 촉진하고, 내피세포에서 NO 생산과 이용을 감소시킬 뿐 아니라 FMD를 억제하며, 내피세포와 백혈구의 상호작용을 활성화시키고 내피세포에서 다양한 염증유발 및 산화 스트레스를 증가시켜 내피세포 기능을 감소시킨다. 내피세포 기능장애는 심혈관 질환 발생의 첫 단계이자, 가장 초기에 발견될 수 있는 표지자로 알려져 있으므로, 식후 고혈당은 산화스트레스 유발 및 내피세포기능장애에 기여하여 혈관합병증을 유발할 수 있다. Postprandial hyperglycemia promotes LDL oxidation, reduces NO production and utilization in endothelial cells, inhibits FMD, activates endothelial cell-leukocyte interactions, increases inflammation induction and oxidative stress in endothelial cells, Reduces cell function. Since endothelial dysfunction is the first stage of cardiovascular disease and is known to be the earliest possible marker, postprandial hyperglycemia may contribute to oxidative stress and endothelial dysfunction leading to vascular complications.
이와 관련하여 한국등록특허 제10-0996985호는 κ-카제인을 유효 성분으로 함유하는 것을 특징으로 하는 GLP-1 분비 촉진제 및 식후 혈당값 상승 억제제, 및 젖 유래의 카제인 단백질을 함유하고, 해당 젖 유래의 카제인 단백질의 60질량% 이상이 κ-카제인인 것을 특징으로 하는 GLP-1 분비 촉진용 음식품 및 식후 혈당값 상승 억제용 음식품을 개시하고 있다. In this regard, Korean Patent No. 10-0996985 discloses a GLP-1 secretion promoting agent and a postprandial increase in blood glucose level inhibitor, which are characterized by containing κ-casein as an active ingredient, and a casein protein derived from milk, Wherein at least 60% by mass of the casein protein of GLP-1 is a κ-casein, and a food or drink for suppressing postprandial increase in blood glucose level.
또한 한국등록특허 제10-0966613호는 혈당상승억제 효능을 갖는 아르기닌 유도체 화합물을 개시하고 있고, 한국등록특허 제10-1155079호는 녹차추출물로부터 분리된 카테킨 칼레이트를 이용한 식후 혈당상승과 비만을 억제하는 조성물을 개시하고 있으며, 한국등록특허 제10-0924478호는 약학적으로 허용되는 음이온 교환 수지인 콜레스티미드를 이용한 식후 과혈당 개선제를 개시하고 있다. Korean Patent No. 10-0966613 discloses an arginine derivative compound having an effect of inhibiting blood glucose elevation. Korean Patent No. 10-1155079 suppresses postprandial increase of blood sugar and obesity using catechin carboxylate isolated from green tea extract And Korean Patent No. 10-0924478 discloses a postprandial hyperglycemia improving agent using cholestimide, which is a pharmaceutically acceptable anion exchange resin.
이러한 연구결과에서 알 수 있듯이, 당뇨의 발병 또는 당뇨병 환자에게서 식후 고혈당 조절이 매우 중요하고, 식후 고혈당을 조절할 수 있는 치료약제들이 적절히 투여된다면 당뇨병 또는 당뇨병성 합병증 예방에 도움이 될 수 있을 것이다. As shown in these results, postprandial hyperglycemia is very important in diabetic patients or diabetic patients, and proper management of postprandial hyperglycemia may be helpful in preventing diabetes or diabetic complications.
본 발명은 당뇨병을 유발할 수 있는 식후 혈당조절이나 당뇨병 환자의 혈당조절 또는 혈관합병증을 예방 또는 감소시킬 수 있는 조성물을 제공하는 것을 목적으로 한다.It is an object of the present invention to provide a composition capable of controlling postprandial blood glucose which can cause diabetes or preventing or reducing blood glucose control or vascular complication in a diabetic patient.
상기와 같은 목적을 달성하기 위하여 본 발명은 아스코르빈산; 니아신; 또는 아스코르빈산 및 니아신;을 유효성분으로 포함하는 식후 혈당상승억제용 조성물을 제공한다. To achieve these and other advantages and in accordance with the purpose of the present invention, as embodied and broadly described herein, Niacin; Or ascorbic acid and niacin as an active ingredient.
본 발명의 일 실시예에 있어서, 상기 아스코르빈산 및 니아신의 중량비는 1:3~3:1인 것을 특징으로 한다. In one embodiment of the present invention, the weight ratio of ascorbic acid and niacin is 1: 3 to 3: 1.
또한 본 발명은 아스코르빈산; 니아신; 또는 아스코르빈산 및 니아신;을 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약학 조성물을 제공한다. The present invention also relates to a composition comprising ascorbic acid; Niacin; Or a pharmaceutical composition for preventing or treating diabetes comprising ascorbic acid and niacin as an active ingredient.
본 발명의 일 실시예에 있어서, 상기 아스코르빈산 및 니아신의 중량비는 1:3~3:1인 것을 특징으로 한다. In one embodiment of the present invention, the weight ratio of ascorbic acid and niacin is 1: 3 to 3: 1.
아울러 본 발명은 아스코르빈산; 니아신; 또는 아스코르빈산 및 니아신;을 유효성분으로 포함하는 당뇨병 예방 또는 개선용 식품 조성물을 제공한다. The present invention also relates to a composition comprising ascorbic acid; Niacin; Or ascorbic acid and niacin as an active ingredient.
본 발명의 일 실시예에 있어서, 상기 아스코르빈산 및 니아신의 중량비는 1:3~3:1인 것을 특징으로 한다. In one embodiment of the present invention, the weight ratio of ascorbic acid and niacin is 1: 3 to 3: 1.
본 발명은 당뇨병을 유발할 수 있는 식후 혈당조절이나 당뇨병 환자의 혈당조절 또는 혈관합병증을 예방 또는 감소시킬 수 있는 조성물을 제공할 수 있다. The present invention can provide a composition capable of controlling postprandial blood glucose which can cause diabetes or preventing or reducing blood glucose control or vascular complications in a diabetic patient.
또한 본 발명은 아스코르빈산 및 니아신을 사용하여 쉽고 간단하게 제조할 수 있으며 약효가 우수한 당뇨병 예방 또는 치료용 약학 조성물을 제공할 수 있다. The present invention also provides a pharmaceutical composition for preventing or treating diabetes mellitus, which can be easily and simply prepared using ascorbic acid and niacin and has excellent pharmaceutical efficacy.
도 1은 아스코르빈산 및 니아신의 Rat Intestinal α-glucosidase에 대한 저해 활성을 나타낸다.
도 2는 아스코르빈산 및 니아신의 porcine pancreatic α-amylase에 대한 저해 활성을 나타낸다.
도 3은 아스코르빈산 및 니아신의 Rat Intestinal sucrase에 대한 저해 활성을 나타낸다.
도 4는 아스코르빈산 및 니아신의 Rat Intestinal maltase에 대한 저해 활성을 나타낸다.
도 5는 아스코르빈산 및 니아신의 Rat Intestinal glucoamylase에 대한 저해 활성을 나타낸다.
도 6은 sucrose에 의한 아스코르빈산의 식후 혈당상승 저해작용을 나타낸다.
도 7은 sucrose에 의한 니아신의 식후 혈당상승 저해작용을 나타낸다.
도 8은 sucrose에 의한 아스코르빈산 및 니아신의 식후 혈당상승 저해작용을 나타낸다. Figure 1 shows the inhibitory activity of ascorbic acid and niacin against Rat intestinal alpha-glucosidase.
Figure 2 shows the inhibitory activity of ascorbic acid and niacin on porcine pancreatic < RTI ID = 0.0 > a-amylase. ≪ / RTI >
Figure 3 shows the inhibitory activity of ascorbic acid and niacin against Rat intestinal sucrase.
4 shows the inhibitory activity of ascorbic acid and niacin against Rat intestinal maltase.
Figure 5 shows the inhibitory activity of ascorbic acid and niacin against Rat intestinal glucoamylase.
Figure 6 shows the postprandial hyperglycemic effect of ascorbic acid induced by sucrose.
Fig. 7 shows the effect of sucrose on the postprandial hyperglycemia of niacin.
Figure 8 shows the postprandial hyperglycemic action of ascorbic acid and niacin by sucrose.
이하 실시예를 바탕으로 본 발명을 상세히 설명한다. 본 발명에 사용된 용어, 실시예 등은 본 발명을 보다 구체적으로 설명하고 통상의 기술자의 이해를 돕기 위하여 예시된 것에 불과할 뿐이며, 본 발명의 권리범위 등이 이에 한정되어 해석되어서는 안 된다. Hereinafter, the present invention will be described in detail based on examples. It is to be understood that the terminology, examples and the like used in the present invention are merely illustrative of the present invention in order to more clearly explain the present invention and to facilitate understanding of the ordinary artisan, and should not be construed as being limited thereto.
본 발명에 사용되는 기술 용어 및 과학 용어는 다른 정의가 없다면 이 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 통상적으로 이해하고 있는 의미를 나타낸다. Technical terms and scientific terms used in the present invention mean what the person skilled in the art would normally understand unless otherwise defined.
본 발명은 아스코르빈산; 니아신; 또는 아스코르빈산 및 니아신;을 유효성분으로 포함하는 식후 혈당상승억제용 조성물에 관한 것이다. The present invention relates to ascorbic acid; Niacin; Or ascorbic acid and niacin as an active ingredient.
식후 혈당상승억제용 조성물로 아스코르빈산 및 니아신을 사용하는 경우, 상기 아스코르빈산 및 니아신의 중량비는 1:3~3:1인 것이 바람직하며, 더욱 바람직하게는 1:1~1:2 인 것이 좋다. When ascorbic acid and niacin are used as a composition for suppressing postprandial rise in blood glucose level, the weight ratio of ascorbic acid and niacin is preferably 1: 3 to 3: 1, more preferably 1: 1 to 1: 2 It is good.
본 발명의 아스코르빈산; 니아신; 또는 아스코르빈산 및 니아신의 혼합물은 Rat intestinal α-glucosidase, Porcine pancreatic α-amylase, Rat intestinal sucrase, Rat intestinal maltase, Rat intestinal glucoamylase에 대한 in vitro 저해활성을 가지며, sucrose의 분해에 관한 in vivo 저해활성을 가진다. Ascorbic acid of the present invention; Niacin; Or a mixture of ascorbic acid and niacin has in vitro inhibitory activity against Rat intestinal α-glucosidase, Porcine pancreatic α-amylase, Rat intestinal sucrase, Rat intestinal maltase and Rat intestinal glucoamylase, and has in vivo inhibitory activity on the degradation of sucrose .
본 발명의 아스코르빈산; 니아신; 또는 아스코르빈산 및 니아신은 식후 혈당상승억제를 위하여 사용될 수 있다. Ascorbic acid of the present invention; Niacin; Alternatively, ascorbic acid and niacin may be used for postprandial hyperglycemia inhibition.
또한 본 발명은 아스코르빈산; 니아신; 또는 아스코르빈산 및 니아신;을 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약학 조성물에 관한 것이다. The present invention also relates to a composition comprising ascorbic acid; Niacin; Or ascorbic acid and niacin as an active ingredient. The present invention also relates to a pharmaceutical composition for preventing or treating diabetes.
약학 조성물로 아스코르빈산 및 니아신을 사용하는 경우, 상기 아스코르빈산 및 니아신의 중량비는 1:3~3:1인 것이 바람직하며, 더욱 바람직하게는 1:1~1:2 인 것이 좋다. When ascorbic acid and niacin are used as the pharmaceutical composition, the weight ratio of ascorbic acid and niacin is preferably 1: 3 to 3: 1, more preferably 1: 1 to 1: 2.
본 발명의 아스코르빈산; 니아신; 또는 아스코르빈산 및 니아신의 혼합물은 항당뇨 활성, 항산화 활성 및 식후 혈당조절 특성이 우수하여 당뇨병의 예방 또는 치료를 위하여 효율적으로 사용될 수 있다. Ascorbic acid of the present invention; Niacin; Or a mixture of ascorbic acid and niacin is excellent in antidiabetic activity, antioxidative activity and postprandial blood glucose controlling property and can be effectively used for prevention or treatment of diabetes.
본 발명의 약학 조성물은 약학 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다. The pharmaceutical compositions of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions.
상기 담체, 부형제 및 희석제로는 락토즈, 텍스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀롤로즈, 메틸 셀롤로즈, 미정질 셀롤로즈, 폴리비닐 피톨리돈, 물, 메틸히드록시벤조에이트, 프로필 히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. The carriers, excipients and diluents include lactose, textol, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
본 발명의 약학 조성물은 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. The pharmaceutical composition of the present invention can be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, oral formulations such as syrups and aerosols, external preparations, suppositories and sterilized injection solutions.
또한 본 발명은 아스코르빈산; 니아신; 또는 아스코르빈산 및 니아신;을 유효성분으로 포함하는 당뇨병 예방 또는 개선용 식품 조성물에 관한 것이다. The present invention also relates to a composition comprising ascorbic acid; Niacin; Or ascorbic acid and niacin as an active ingredient.
식품 조성물로 아스코르빈산 및 니아신을 사용하는 경우, 상기 아스코르빈산 및 니아신의 중량비는 1:3~3:1인 것이 바람직하며, 더욱 바람직하게는 1:1~1:2 인 것이 좋다. When ascorbic acid and niacin are used as the food composition, the weight ratio of ascorbic acid and niacin is preferably 1: 3 to 3: 1, more preferably 1: 1 to 1: 2.
식품은 각종 식품류, 캔디, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류 등의 형태일 수 있고, 분말, 과립, 정제, 캡슐, 음료 등의 형태로 제공될 수 있다. The food may be in the form of various foods, candy, beverage, gum, tea, vitamin complex, health functional food, etc., and may be provided in the form of powder, granule, tablet, capsule, drink or the like.
이하 실시예를 통해 본 발명을 상세히 설명한다. 하기 실시예는 본 발명의 실시를 위하여 예시된 것일 뿐, 본 발명의 내용이 하기 실시예에 의하여 한정되는 것은 아니다. Hereinafter, the present invention will be described in detail with reference to examples. The following examples are intended to illustrate the practice of the present invention and are not intended to limit the scope of the present invention.
(실시예 1) 아스코르빈산 및 니아신의 In-vitro 항당뇨 활성 (Example 1) In-vitro antidiabetic activity of ascorbic acid and niacin
(가) Rat intestinal α-glucosidase inhibition assay (A) Rat intestinal α-glucosidase inhibition assay
● 효소: 래트 소장 아세톤 분말● Enzyme: rat small intestine acetone powder
● substrate: PNP-glycoside(pNPG, p-Nitrophenyl α-D-glucopyranoside) ● substrate: PNP-glycoside (pNPG, p-Nitrophenyl α-D-glucopyranoside)
래트 소장 아세톤 분말 300mg 에 0.1M sodium phosphate buffer(pH 6.9) 9㎖을 첨가하여 30초간 12회 ice water bath에서 초음파처리 후, 13,000rpm, 4℃에서 30분간 원심분리 하였다. To 300 mg of rat small intestine acetone powder, 9 ml of 0.1 M sodium phosphate buffer (pH 6.9) was added, sonicated 12 times in an ice water bath for 30 seconds, and then centrifuged at 13,000 rpm at 4 ° C for 30 minutes.
원심분리 후 상층액을 회수하여 Rat intestinal α-glucosidase Inhibition assay에 사용하였다. Rat α-glucosidase solution 100㎕와 Sample solution 50㎕를 넣고 37℃에서 10분간 반응시킨 후, 50㎕의 5mM pNPG 용액을 가하여 37℃에서 30분간 반응시켰다. After centrifugation, supernatant was collected and used for Rat intestinal α-glucosidase inhibition assay. 100 μl of Rat α-glucosidase solution and 50 μl of sample solution were added and reacted at 37 ° C for 10 minutes. Then, 50 μl of 5 mM pNPG solution was added and reacted at 37 ° C for 30 minutes.
반응이 끝난 후, 405nm에서 ELISA reader를 사용하여 흡광도를 측정하여 rat intestinal α-glucosidase에 대한 저해활성을 분석하였다. After the reaction, the absorbance was measured using an ELISA reader at 405 nm to analyze the inhibitory activity against rat intestinal α-glucosidase.
아스코르빈산과 니아신이 나타내는 Rat Intestinal α-glucosidase에 대한 저해 활성은 도 1에 제시된다. The inhibitory activity against ascitic α-glucosidase, represented by ascorbic acid and niacin, is shown in FIG.
아스코르빈산과 니아신 모두 0.5, 1, 2 mg/㎖ 농도에서 농도 의존적으로 저해 활성을 나타내었다. Both ascorbic acid and niacin showed concentration - dependent inhibitory activity at 0.5, 1, and 2 mg / ㎖ concentrations.
아스코르빈산의 50% 저해활성 농도(IC50)는 1.15 mg/㎖ 이고, 니아신의 50% 저해활성 농도(IC50)는 0.96 mg/㎖ 이다. The 50% inhibitory activity concentration (IC 50 ) of ascorbic acid was 1.15 mg / ml and the 50% inhibitory activity concentration (IC 50 ) of niacin was 0.96 mg / ml.
(나) Porcine pancreatic α-amylase inhibition assay(B) Porcine pancreatic α-amylase inhibition assay
● 효소: porcine pancreatic α-amylase ● Enzyme: porcine pancreatic α-amylase
● substrate: 1% starch solution in 0.02M sodium phosphate buffer(pH 6.9)Substrate: 1% starch solution in 0.02M sodium phosphate buffer (pH 6.9)
● coloring reagent: 3,5-dinitrosalicylic acid solution(DNS) in 2M NaOH with 30% sodium potassium tartrate tetrahydrate● coloring reagent: 3,5-dinitrosalicylic acid solution (DNS) in 2M NaOH with 30% sodium potassium tartrate tetrahydrate
0.02M 소듐 포스페이트 버퍼(pH 6.9; 0.006M 소듐 클로라이드 포함)에 녹인 1U 농도의 porcine pancreatic α-amylase 용액 300㎕에 샘플 용액 200㎕을 넣고 25℃에서 10분간 배양시켰다. 200 μl of the sample solution was added to 300 μl of 1 U concentration of porcine pancreatic α-amylase solution dissolved in 0.02 M sodium phosphate buffer (pH 6.9; containing 0.006 M sodium chloride), followed by incubation at 25 ° C. for 10 minutes.
이 용액에 25℃에서 10분 동안 예비 배양시킨 1% starch 용액 500㎕를 첨가하여 25℃에서 10분간 반응시켰다. To this solution was added 500 μl of a 1% starch solution preliminarily incubated at 25 ° C for 10 minutes and reacted at 25 ° C for 10 minutes.
30% Rochelle 염에 녹인 1% DNS 용액을 1㎖ 첨가하여 반응을 정지시킨 후 boiling water bath에서 5분간 처리한 다음 실온으로 식히고 10㎖의 증류수를 첨가하였다. The reaction was stopped by adding 1 ml of 1% DNS solution dissolved in 30% Rochelle salt, treated in a boiling water bath for 5 minutes, cooled to room temperature and added with 10 ml of distilled water.
α-amylase에 의해서 기질로부터 분해된 당과 DNS 용액과의 반응액을 540nm에서 ELISA reader를 사용하여 흡광도를 측정하였으며, 샘플 대신 샘플을 용해시킨 용매를 넣은 것을 대조구로 하였다.Absorbance was measured at 540 nm using an ELISA reader, and a solution in which the sample was dissolved instead of the sample was used as a control.
아스코르빈산과 니아신이 나타내는 Porcine pancreatic α-amylase에 대한 저해 활성은 도 2에 제시된다. The inhibitory activity against porcine pancreatic α-amylase, represented by ascorbic acid and niacin, is shown in FIG.
아스코르빈산은 1, 2, 5 mg/㎖ 농도에서 농도 의존적으로 저해 활성을 나타내고, 니아신은 0.5, 1, 2.5 mg/㎖ 농도에서 농도 의존적으로 저해 활성을 나타내었다. Ascorbic acid showed inhibitory activity at concentration of 1, 2 and 5 mg / ㎖, and niacin showed inhibitory activity at concentration of 0.5, 1, and 2.5 mg / ㎖ in a concentration - dependent manner.
아스코르빈산의 50% 저해활성 농도(IC50)는 2.06 mg/㎖ 이고, 니아신의 50% 저해활성 농도(IC50)는 2.39 mg/㎖ 이다. The 50% inhibitory activity concentration (IC 50 ) of ascorbic acid was 2.06 mg / ml and the 50% inhibitory activity concentration (IC 50 ) of niacin was 2.39 mg / ml.
(다) Rat intestinal glucose oxidase assay(Maltose, Sucrose, Glucoamylase) (C) Rat intestinal glucose oxidase assay (Maltose, Sucrose, Glucoamylase)
● 효소: 래트 소장 아세톤 분말 ● Enzyme: rat small intestine acetone powder
● substrate: 100mM maltose, 200mM sucrose, 1% starch solutionSubstrate: 100 mM maltose, 200 mM sucrose, 1% starch solution
● Oxidase kit: Glucose oxidase/peroxidase reagent(Sigma G3660), O-Dianisidine reagent(Sigma D2679)Oxidase kit: Glucose oxidase / peroxidase reagent (Sigma G3660), O-Dianisidine reagent (Sigma D2679)
효소는 래트 소장 아세톤 분말(Sigma S9765)을 사용하였고 기질은 maltose, sucrose, starch(Junsei)를 사용하였다. Rat small intestine acetone powder (Sigma S9765) was used as the enzyme and maltose, sucrose, starch (Junsei) were used as substrates.
래트 소장 아세톤 분말 100㎎을 3㎖의 0.9% NaCl 용액(Junsei)에 첨가한 후 30초간 12회 iced water bath에서 초음파 조사한 다음 10,000rpm, 4℃에서 30분간 원심 분리하였다. 100 mg of the rat small intestine acetone powder was added to 3 ml of 0.9% NaCl solution (Junsei), sonicated in an iced water bath for 12 seconds for 30 seconds, and then centrifuged at 10,000 rpm and 4 ° C for 30 minutes.
분리된 상층액을 실험에 사용하였다. Separated supernatants were used for the experiments.
96 clear plate에 100㎕의 rat α-glucosidase 용액에 50㎕의 시료를 넣은 다음 37℃ 인큐베이터에서 10분간 정치시켰다. 50 μl of sample was added to 100 μl of rat α-glucosidase solution on a 96-well plate and allowed to stand in a 37 ° C. incubator for 10 minutes.
각각의 실험 방법에 따라 50㎕의 100mM maltose, 또는 200mM sucrose, 1% starch 용액을 가한 다음 37℃에서 30분간 반응시키고 30분간 반응 사이에 Glucose oxidase/peroxidase reagent(Sigma G3660)와 O-Dianisidine reagent(Sigma D2679)를 섞은 용액 1㎖을 2㎖ Epp Tube에 넣은 후 37℃ 인큐베이터에서 5분간 방치하여 온도를 37℃로 맞춘 후, 앞서 30분 동안 반응한 래트 소장 아세톤 분말과 샘플, 기질 용액 혼합시약 200㎕을 취하여 1㎖ Glucose oxidase/peroxidase reagent와 O-Dianisidine reagent과 반응시킨 후 37℃ 인큐베이터에서 10분간 반응시켰다. 50 μl of 100mM maltose or 200mM sucrose and 1% starch solution was added to each well and incubated at 37 ° C for 30 minutes. The reaction was carried out for 30 minutes with glucose oxidase / peroxidase reagent (Sigma G3660) and O-Dianisidine reagent Sigma D2679) was placed in a 2 ml Epp tube and allowed to stand for 5 minutes at 37 ° C in an incubator. The temperature was adjusted to 37 ° C. Were reacted with 1 ml of glucose oxidase / peroxidase reagent and O-Dianisidine reagent, and reacted for 10 minutes at 37 ° C in an incubator.
각각의 2㎖ Epp tube에 12N 황산 1㎖을 첨가하여 반응을 정지시킨 후 96 clear plate에 200㎕씩 넣은 후 540nm에서 ELISA reader를 사용하여 흡광도를 측정하여 Rat intestinal glucose oxidase(maltose, sucrose, glucoamylase)에 대한 저해활성을 분석하였다. The reaction was stopped by adding 1 ml of 12N sulfuric acid to each 2 ml Epp tube, and 200 μl of the solution was added to a 96-well plate. The absorbance was measured at 540 nm using an ELISA reader to determine the amount of Rat intestinal glucose oxidase (maltose, sucrose, glucoamylase) Were analyzed.
시료 대신 시료를 용해시킨 용매를 넣은 것을 대조구로 하였다. A solution containing a sample dissolved in place of the sample was used as a control.
아스코르빈산과 니아신이 나타내는 Sucrase에 대한 저해 활성은 도 3에 제시된다. The inhibitory activity against ascorbic acid and niacin is shown in Fig.
아스코르빈산은 0.1, 0.2, 0.5 mg/㎖ 농도에서 농도 의존적으로 저해 활성을 나타내고 있으나, 니아신은 저해 활성을 나타내지 않았다. Ascorbic acid showed inhibitory activity at concentrations of 0.1, 0.2 and 0.5 mg / ml, but niacin showed no inhibitory activity.
아스코르빈산의 50% 저해활성 농도(IC50)는 0.24 mg/㎖ 이다. The 50% inhibitory activity concentration (IC 50 ) of ascorbic acid is 0.24 mg / ml.
아스코르빈산과 니아신이 나타내는 Maltase에 대한 저해 활성은 도 4에 제시된다. The inhibitory activity against maltase exhibited by ascorbic acid and niacin is shown in Fig.
아스코르빈산은 0.2, 0.5, 1 mg/㎖ 농도에서 농도 의존적으로 저해 활성을 나타내고 있으나, 니아신은 저해 활성을 나타내지 않았다. Ascorbic acid showed inhibitory activity at concentrations of 0.2, 0.5 and 1 mg / ml, but niacin showed no inhibitory activity.
아스코르빈산의 50% 저해활성 농도(IC50)는 1.2 mg/㎖ 이다. The 50% inhibitory activity concentration (IC 50 ) of ascorbic acid is 1.2 mg / ml.
아스코르빈산과 니아신이 나타내는 Glucoamylase에 대한 저해 활성은 도 5에 제시된다. The inhibitory activity against glucoamylase represented by ascorbic acid and niacin is shown in Fig.
아스코르빈산은 0.2, 0.5, 1 mg/㎖ 농도에서 농도 의존적으로 저해 활성을 나타내고 있으나, 니아신은 저해 활성을 나타내지 않았다. Ascorbic acid showed inhibitory activity at concentrations of 0.2, 0.5 and 1 mg / ml, but niacin showed no inhibitory activity.
아스코르빈산의 50% 저해활성 농도(IC50)는 0.69 mg/㎖ 이다. The 50% inhibitory activity concentration (IC 50 ) of ascorbic acid is 0.69 mg / ml.
아래 표 1은 아스코르빈산 및 니아신의 Rat intestinal α-glucosidase, Porcine pancreatic α-amylase, Rat intestinal sucrase, Rat intestinal maltase, Rat intestinal glucoamylase에 대한 50% 저해활성 농도(IC50)를 나타내고 있다. Table 1 below shows the 50% inhibitory activity concentration (IC 50 ) for Rat intestinal α-glucosidase, Porcine pancreatic α-amylase, Rat intestinal sucrase, Rat intestinal maltase and Rat intestinal glucoamylase of ascorbic acid and niacin.
아스코르빈산은 모든 소화효소에서 높은 저해활성을 나타내고 있으며, 특히 Sucrase에 대한 50% 저해활성 농도(IC50)가 0.24 mg/㎖로 가장 낮은 수치를 나타내었다. Ascorbic acid showed a high inhibitory activity on all digestive enzymes, and the lowest concentration of 50% inhibitory activity (IC 50 ) against sucrase was 0.24 mg / ㎖.
아스코르빈산은 소화효소에 대해 0.24~2.06 mg/㎖의 50% 저해활성 농도(IC50)를 나타내었다. Ascorbic acid exhibited a 50% inhibitory activity concentration (IC 50 ) of 0.24 to 2.06 mg / ml against digestive enzymes.
니아신은 Rat intestinal α-glucosidase 및 Porcine pancreatic α-amylase에 대해 높은 저해활성을 나타내고 있으나, 나머지 효소에 대해서는 저해 활성을 나타내지 않았다. Niacin showed high inhibitory activity against Rat intestinal α-glucosidase and Porcine pancreatic α-amylase, but did not inhibit the other enzymes.
니아신은 Rat intestinal α-glucosidase 및 Porcine pancreatic α-amylase에 대해 0.96~2.39 mg/㎖의 50% 저해활성 농도(IC50)를 나타내었다. Niacin showed a 50% inhibitory activity (IC 50 ) of 0.96 to 2.39 mg / ml against Rat intestinal α-glucosidase and Porcine pancreatic α-amylase.
아래 표 2는 아스코르빈산 및 니아신을 혼합하여 사용한 경우, Rat intestinal α-glucosidase에 대한 50% 저해활성 농도(IC50)를 나타내고 있다. Table 2 below shows the 50% inhibitory activity concentration (IC 50 ) for Rat intestinal α-glucosidase when ascorbic acid and niacin are mixed.
(중량비) Ascorbic acid: niacin
(Weight ratio)
아스코르빈산과 니아신의 중량비가 1:2인 경우, 50% 저해활성 농도(IC50)가 0.56 mg/㎖로 가장 낮은 수치를 나타내었다. When the weight ratio of ascorbic acid to niacin was 1: 2, the lowest concentration of 50% inhibitory activity (IC 50 ) was 0.56 mg / ml.
또한 아스코르빈산과 니아신의 중량비가 1:3~3:1인 경우, 50% 저해활성 농도(IC50)가 0.56~0.77 mg/㎖로 아스코르빈산만 사용한 경우와 니아신만 사용한 경우에 비해 더 낮은 수치를 나타내었다. In addition, when ascorbic acid and niacin were used in a weight ratio of 1: 3 to 3: 1, the concentration of 50% inhibitory activity (IC 50 ) was 0.56 to 0.77 mg / Respectively.
따라서 아스코르빈산 및 니아신을 혼합하여 사용하는 것이 아스코르빈산만 사용한 경우나 니아신만 사용하는 경우에 비해 식후 혈당상승억제, 당뇨병 예방 또는 치료에 더 유효함을 알 수 있다. Therefore, it can be seen that the use of ascorbic acid and niacin in combination is more effective in suppressing postprandial increase in blood sugar and prevention or treatment of diabetes compared to the case of using only ascorbic acid or niacin alone.
또한 아스코르빈산 및 니아신을 혼합하여 사용하는 경우, 아스코르빈산 및 니아신의 중량비는 1:3~3:1인 것이 바람직하며, 더욱 바람직하게는 1:1~1:2 인 것이 좋다. When a mixture of ascorbic acid and niacin is used, the weight ratio of ascorbic acid and niacin is preferably 1: 3 to 3: 1, more preferably 1: 1 to 1: 2.
(실시예 2) 아스코르빈산 및 니아신의 In-vivo test에 의한 식후 혈당조절 작용 (Example 2) Post-prandial glucose control by in-vivo test of ascorbic acid and niacin
(가) 실험동물(A) Experimental animals
생후 4주령의 수컷 SD rat을 라온바이오로부터 구입하여 동물 사육실에서 사육 후, 생후 6주령 때 건강한 동물만을 선별 후 실험에 사용하였다. Four - week - old male SD rats were purchased from Raon Bio and used in the experiment after selection of healthy animals at 6 weeks of age.
(나) Sucrose 섭취에 대한 혈당상승 억제작용 평가(B) Evaluation of inhibition of blood glucose elevation on sucrose intake
실험동물을 실험 전 20시간 이상 절식시킨 후, 2g/kg body weight의 Sucrose에 아스코르빈산, 나이신, 및 아스코르빈산과 나이신의 혼합물을 0.1g/kg, 0.5g/kg의 농도로 투여하였으며, 시료는 경구 투여용 존대를 이용하여 경구 투여하였다. Experimental animals were fasted for more than 20 hours before the experiment, and a mixture of ascorbic acid, nisin, and ascorbic acid and nisin was administered at a concentration of 0.1 g / kg, 0.5 g / kg to a sucrose of 2 g / kg body weight , And the samples were orally administered by oral route for oral administration.
투여군은 5군으로 각 군당 6마리씩 사용하였다. 경구 투여 후 0.5, 1, 2 및 3시간에 래트 꼬리 정맥으로부터 채혈하여 정맥혈의 혈당 농도 변화를 혈당계(Caresens Ⅱ)로 측정하였다.In
Sucrose에 의한 아스코르빈산의 식후 혈당상승 저해작용은 도 6에 제시된다. The postprandial hyperglycemic effect of ascorbic acid by sucrose is shown in Fig.
아스코르빈산의 섭취 후 혈당변화를 측정해 본 결과, 아스코르빈산의 섭취 후 0.5시간에 control 군은 247.67±30.69 mg/dl을 나타내고 있으며, 0.5 g/kg-body weight 투여군은 201.92±17.50 mg/dl을 나타내므로, 약 18%의 식후 혈당 상승을 억제하는 것을 알 수 있다.In the 0.5 g / kg-body weight group, the control group showed 247.67 ± 30.69 mg / dl at 0.5 hour after ingestion of ascorbic acid, and 201.92 ± 17.50 mg / dl, it can be seen that the postprandial increase in blood glucose is suppressed by about 18%.
또한 식후 1시간까지 control 군은 248.38±37.46 mg/dl 이고, 0.5 g/kg-body weight 투여군은 230.20±12.73 mg/dl 으로 약 7%의 식후 혈당 상승을 억제하는 것을 알 수 있다. In the control group, 248.38 ± 37.46 mg / dl was administered until 1 hour after the meal, and 230.20 ± 12.73 mg / dl in the 0.5 g / kg-body weight group.
이러한 결과를 통해 아스코르빈산은 자당섭취 후 혈당의 흡수를 저해하여, 혈당감소 및 흡수지연 효과를 나타냄을 알 수 있다. These results show that ascorbic acid inhibits the absorption of glucose after sucrose ingestion, and shows a blood glucose reduction and an absorption delay effect.
Sucrose에 의한 니아신의 식후 혈당상승 저해작용은 도 7에 제시된다. The postprandial hyperglycemic effect of niacin by sucrose is shown in Fig.
니아신의 섭취 후 혈당변화를 측정해 본 결과, 니아신의 섭취 후 0.5시간에 control 군은 247.67±30.69 mg/dl 이고, 0.5 g/kg-body weight 투여군은 211.50±17.74 mg/dl 이어서 약 14%의 식후 혈당 상승을 억제하는 것을 알 수 있다. As a result of measuring the blood glucose change after ingestion of niacin, the control group was 247.67 ± 30.69 mg / dl at 0.5 hour after ingestion of niacin and 211.50 ± 17.74 mg / dl at 0.5 g / kg-body weight group, And suppress the increase of postprandial blood glucose.
또한 식후 1시간까지 control 군은 248.38±37.46 mg/dl 이고, 0.5 g/kg-body weight 투여군은 225.67±21.12 mg/dl 이어서, 약 9%의 식후 혈당 상승을 억제하는 것을 알 수 있다. In the control group, 248.38 ± 37.46 mg / dl and 0.5 g / kg-body weight group were 225.67 ± 21.12 mg / dl until 1 hour after the meal, respectively.
이러한 결과를 통해 니아신은 자당섭취 후 혈당의 흡수를 저해하여, 혈당감소 및 흡수지연 효과를 나타냄을 알 수 있다. These results indicate that niacin inhibits the absorption of glucose after sucrose ingestion, and thus exhibits an effect of reducing blood glucose and delaying absorption.
Sucrose에 의한 아스코르빈산 및 니아신을 혼합하여 사용한 경우(아스코르빈산 및 니아신의 중량비는 1:2)의 식후 혈당상승 저해작용은 도 8에 제시된다. The postprandial hyperglycemic effect of ascorbic acid and niacin in combination with sucrose (1: 2 by weight ratio of ascorbic acid and niacin) is shown in FIG.
아스코르빈산 및 니아신의 섭취 후 혈당변화를 측정해 본 결과, 섭취 후 1시간에 control 군은 248.75±25.14 mg/dl 이고, 0.5 g/kg-body weight 투여군은 194.33±23.96 mg/dl 이어서, 약 21%의 식후 혈당 상승을 억제하는 것을 알 수 있다. Ascorbic acid and niacin were measured at 248.75 ± 25.14 mg / dl in the control group and 194.33 ± 23.96 mg / dl in the 0.5 g / kg-body weight group at 1 hour after ingestion, 21% of postprandial hyperglycemia.
또한 식후 2시간까지 control 군은 197.08±38.62 mg/dl 이고, 0.5 g/kg-body weight 투여군은 156.75±15.81 mg/dl 이어서, 약 20%의 식후 혈당 상승을 억제하는 것을 알 수 있다. In the control group, it was 197.08 ± 38.62 mg / dl up to 2 hours after the meal and 156.75 ± 15.81 mg / dl in the 0.5 g / kg body weight group.
이러한 결과를 통하여 아스코르빈산 및 니아신을 혼합하여 섭취하는 경우 자당섭취 후 혈당의 흡수를 저해하여, 혈당감소 및 흡수지연 효과를 나타냄을 알 수 있다. These results show that when mixed with ascorbic acid and niacin, the absorption of glucose after sucrose ingestion is inhibited, and the blood glucose reduction and absorption delay effect are exhibited.
또한 아스코르빈산 및 니아신을 특정 혼합비로 혼합하여 섭취하는 경우, 각각을 단독으로 섭취하는 경우에 비해 혈당상승억제 효과가 우수함을 알 수 있다. In addition, when ascorbic acid and niacin are mixed at a specific mixing ratio, they are superior in the effect of suppressing the increase in blood glucose as compared with the case of ingesting them individually.
Claims (6)
Ascorbic acid; Niacin; Or ascorbic acid and niacin as an active ingredient.
상기 아스코르빈산 및 니아신의 중량비는 1:3~3:1인 것을 특징으로 하는 식후 혈당상승억제용 조성물.
The method according to claim 1,
Wherein the weight ratio of ascorbic acid and niacin is 1: 3 to 3: 1.
Ascorbic acid; Niacin; Or ascorbic acid and niacin as an active ingredient.
상기 아스코르빈산 및 니아신의 중량비는 1:3~3:1인 것을 특징으로 하는 당뇨병 예방 또는 치료용 약학 조성물.
The method of claim 3,
Wherein the weight ratio of ascorbic acid to niacin is 1: 3 to 3: 1.
Ascorbic acid; Niacin; Or a composition for preventing or improving diabetes comprising ascorbic acid and niacin as an active ingredient.
상기 아스코르빈산 및 니아신의 중량비는 1:3~3:1인 것을 특징으로 하는 당뇨병 예방 또는 개선용 식품 조성물.
6. The method of claim 5,
Wherein the weight ratio of ascorbic acid and niacin is 1: 3 to 3: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170177508A KR102043461B1 (en) | 2017-12-21 | 2017-12-21 | A composition for postprandial anti-hyperglycemia comprising ascorbic acid and niacin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170177508A KR102043461B1 (en) | 2017-12-21 | 2017-12-21 | A composition for postprandial anti-hyperglycemia comprising ascorbic acid and niacin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190075702A true KR20190075702A (en) | 2019-07-01 |
| KR102043461B1 KR102043461B1 (en) | 2019-11-11 |
Family
ID=67255388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170177508A KR102043461B1 (en) | 2017-12-21 | 2017-12-21 | A composition for postprandial anti-hyperglycemia comprising ascorbic acid and niacin |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102043461B1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100924478B1 (en) | 2001-07-30 | 2009-11-03 | 미쓰비시 타나베 파마 코퍼레이션 | Drugs for ameliorating postcibal hyperglycemia |
| KR100966613B1 (en) | 2009-12-21 | 2010-06-29 | 한남대학교 산학협력단 | Method for manufacturing composition comprising arginine derivative or its salt showing the effect of suppressing the elevation of blood sugar level |
| KR100996985B1 (en) | 2005-09-30 | 2010-11-26 | 모리나가 뉴교 가부시키가이샤 | Agent for promoting glucagon-like peptide 1 secretion, food or drink for promoting glucagon-like peptide 1 secretion, agent for inhibiting postprandial increase in blood sugar level and food or drink for inhibiting postprandial increase in blood sugar level |
| KR101155079B1 (en) | 2011-02-09 | 2012-06-11 | (주) 엔유씨생활과건강 | Composition for use of suppression of blood glucose increase and inhibition of obesity comprising gamma-polyglutamic acid and galated catechin |
-
2017
- 2017-12-21 KR KR1020170177508A patent/KR102043461B1/en active IP Right Grant
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100924478B1 (en) | 2001-07-30 | 2009-11-03 | 미쓰비시 타나베 파마 코퍼레이션 | Drugs for ameliorating postcibal hyperglycemia |
| KR100996985B1 (en) | 2005-09-30 | 2010-11-26 | 모리나가 뉴교 가부시키가이샤 | Agent for promoting glucagon-like peptide 1 secretion, food or drink for promoting glucagon-like peptide 1 secretion, agent for inhibiting postprandial increase in blood sugar level and food or drink for inhibiting postprandial increase in blood sugar level |
| KR100966613B1 (en) | 2009-12-21 | 2010-06-29 | 한남대학교 산학협력단 | Method for manufacturing composition comprising arginine derivative or its salt showing the effect of suppressing the elevation of blood sugar level |
| KR101155079B1 (en) | 2011-02-09 | 2012-06-11 | (주) 엔유씨생활과건강 | Composition for use of suppression of blood glucose increase and inhibition of obesity comprising gamma-polyglutamic acid and galated catechin |
Non-Patent Citations (1)
| Title |
|---|
| 이세운 저, ‘수용성 비타민의 혈당상승억제 및 항산화 활성에 관한 연구’, 2015, 한남대학교 대학원 식품영양학과 석사학위논문 (2015.08.)* * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102043461B1 (en) | 2019-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5342644B2 (en) | Composition for controlling blood sugar increase | |
| US9399043B2 (en) | Composition having lipolysis-promoting effect | |
| WO2006119038A1 (en) | Compositions and methods for controlling glucose uptake | |
| JP2009077696A (en) | Food containing extract of salacia plant and flavonoid | |
| WO2017159679A1 (en) | Polysaccharide digestion inhibitor | |
| JP2021527669A (en) | Compositions and Methods for Relieving or Treating Fibrosis | |
| CN115998838B (en) | Composition with blood sugar reducing synergistic effect and application thereof | |
| KR102043461B1 (en) | A composition for postprandial anti-hyperglycemia comprising ascorbic acid and niacin | |
| KR20130104132A (en) | Composition for suppressing elevation of blood sugar level comprising onion coat extract and manufacturing method of onion coat extract | |
| KR101676297B1 (en) | Composition for supressing of blood sugar level | |
| KR101710780B1 (en) | Pharmaceutical composition for preventing or treating obesity or lipid related metabolic disease comprising extract of Atractylodis macrocephalae rhizoma | |
| US20060240120A1 (en) | Composition for lowering blood glucose | |
| JPWO2016132483A1 (en) | Human chymase inhibitor and drug for preventing or treating diseases associated with human chymase activity | |
| JP2009137920A (en) | Glycogen phosphorylase inhibitor | |
| EP3900725A1 (en) | Composition comprising cyp4a-inhibiting compound as active ingredient for preventing or treating metabolic diseases | |
| KR20230057134A (en) | A composition for postprandial anti-hyperglycemia comprising Nipa Fruticans Wurmb extract | |
| KR102556243B1 (en) | A pharmaceutical composition comprising amadori rearrangement compound for preventing or treating obesity | |
| KR20110100880A (en) | Composition comprising quercetin for lowering blood glucose | |
| JP2015127320A (en) | Oral pharmaceutical composition and functional food | |
| WO2021187942A1 (en) | Use of cyclo-hispro (chp) for lowering blood pressure | |
| TWI843442B (en) | A composition for postprandial anti-hyperglycemia comprising coffee extract | |
| KR20230174959A (en) | A composition for postprandial anti-hyperglycemia comprising red ginseng extract with high content of Amadori compound | |
| KR101188743B1 (en) | New amadori compound and its use | |
| KR101319552B1 (en) | Compositions for prevention or treatment of diabetes mellitus or diabetic complications containing stings of Gleditsia sinensis extracts as an active ingredient | |
| WO2021215700A1 (en) | Composition for preventing or treating ischemia reperfusion injury comprising nadph oxidase 1 inhibitor as active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| N231 | Notification of change of applicant | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |